Outbreaks of hepatitis A virus (HAV) infection have re-emerged among men who have sex with men (MSM) across the Asia-Pacific region, the United States, and several European countries since 2015. In Taiwan the suboptimal response to HAV vaccine among MSM living with HIV raises serious concerns about the personal-level and population-level effectiveness of HAV vaccination. This pattern of under vaccination to HAV among MSM has also been seen in the outbreak of hepatitis A in the key population in Australia that warranted State governments offering funded vaccination to curb this outbreak.
This session covered the various aspects African and European countries encountered during their PrEP implementation and its uptake. What lessons were learned that helps guided future rollout of the program to various key populations who are at greater risk of HIV acquisition then the general population. I have only selected a few from the many presentations from this session to provide an overview of what was covered.
This session covered pre-exposure prophylaxis (PrEP) experiences from Australia, Netherlands, United Kingdom, Thailand and United States’ perspectives. I have summarised selected presentations briefly here as it depicts the use of PrEP in the real world and what are the implications that one needs to factor into the provision to various patient populations.
The panel of speakers in this session were represented from high-, middle-, low- and lower-middle-income (LIC/LMICs) countries addressing the benefits and barriers of generic ARV use. Until recently, the use of low-cost and generic ARVs in high-income countries such as the USA has been relatively limited. This is in contrast with low- and lower-middle-income countries (LICs/LMICs) where the availability of generic ARVs have helped millions to be on treatment.